Related Experiment Video
Updated: May 3, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
The evolving landscape of metastatic renal cell carcinoma
Daniel Y C Heng1, Toni K Choueiri1
1From the Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.
Abstract:
The treatment paradigm in metastatic renal cell carcinoma (mRCC) has evolved over the last 5 years. There are now seven approved targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The use of targeted therapy, sequences, combinations, and investigational compounds will be discussed. Prognostic and predictive tools are detailed, although much work must be done to find predictive biomarkers in an effort to individualize therapy for patients.
Insights
The treatment for metastatic renal cell carcinoma (mRCC) has advanced with seven new targeted therapies. Future research aims to find biomarkers for personalized treatment strategies.
Area of Science:
- Oncology
- Medical Research
Background:
- The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly changed in recent years.
- Seven targeted therapies focusing on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways are now approved.
Purpose of the Study:
- To discuss the evolving treatment paradigm in mRCC.
- To review approved targeted therapies, their sequences, combinations, and investigational agents.
- To highlight the importance of prognostic and predictive tools for individualizing patient therapy.
Main Methods:
- Review of approved targeted therapies for mRCC.
- Discussion of treatment sequences and combinations.
- Analysis of prognostic and predictive tools.
Main Results:
- Seven targeted therapies are currently approved for mRCC.
- The use of targeted therapies, including combinations and investigational compounds, is a key focus.
- Prognostic and predictive tools are available but require further development.
Conclusions:
- The treatment of mRCC has evolved with the introduction of multiple targeted therapies.
- Individualizing therapy through predictive biomarkers remains a critical area for future research.
- Further investigation is needed to optimize treatment strategies and outcomes for mRCC patients.
More Related Videos
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...